Illumina has entered a collaboration with Genomics England to develop a new platform and knowledge base, which can be used to improve and automate genome interpretation.
The tools, being developed, will be operated within Genomics’s secure database to allow researchers and clinicians to access information and reports more readily.
The partnership will develop and deliver systems for clinical interpretation, decision support and knowledge curation for the 100,000 Genomes Project.
Under the deal, new informatics tools will be developed to support the delivery of genomic clinical and research services at a population scale to the NHS Genomic Medicine Centers and the Genomics England Clinical Interpretation Partners.
It is expected that all of the tools will include open application programming interfaces so that other bioinformatics solution partners can continue to provide services within the project.
The deal will see Genomics provide access to whole genome sequence and de-identified phenotypic data for the development of this suite of tools for personalised medicine.
Illumina chairman and CEO Jay Flatley said: "Our partnership with Genomics England will help change the way healthcare is practiced.
"The development of our suite of technologies and platforms is critical to enabling physicians in the future to make educated diagnoses based on a patient’s genome, which will lead to better health outcomes."
The deal also includes the ability for Genomics England to work with Illumina’s other tools, NextBio and BaseSpace, for data access and genomic data management.
Illumina will provide tools to Genomics researchers and the GENE Consortium part of the 100,000 Genomes dataset as a pilot within NextBio Clinical, which will allow group analysis of complex phenotypic and genotypic information from de-identified genomes.
Genomics England executive chairman John Chisholm said: "This agreement allows Genomics England to access Illumina’s bioinformatics knowledge and experience to support our ambitions of transforming patient care and research.
"We are both committed to patients benefiting from genomic analysis across the NHS and to supporting clinicians and researchers in finding new genomic insights. Illumina is our key sequencing partner and they are now able to also support us, alongside our other partners, in solving the challenges of delivering clinical reporting and knowledge curation at a national scale."